Analytical Evidence Report

HPLC-DAD results for the submitted Retatrutide sample

REPORT NUMBER
DAYL-RETA-10-102626

GENERATED
November 27, 2026

Retatrutide

Results and chromatograms

Sample 6026_0362 | Client report DAYL-RETA-10-102626

Lot # TNPS-RETA10-001 | Client: TrueNorth Peptide Supply

Laboratory Analysis: LAB-CA-01

VIAL PHOTOGRAPH


SAMPLE INFORMATION	
Label claim:	**10 mg**
Received:	**Oct 30, 2026**
Status:	**Data complete**
Submitted as:	**Retatrutide**

ANALYSIS	
Purity at:	**214 nm**
Amount at:	**214 nm**
Run length:	**12.00 min**

RESULTS AT A GLANCE

PROJECTED AMOUNT	HPLC PURITY	CONTENT VS. LABEL	IDENTITY (LC-MS)
12.89 mg	**99.96%**	**128.9%**	**Confirmed**
BASED ON SAMPLE PREPARATION	214 NM AREA PERCENT	12.89 MG OF 10 MG CLAIMED	4+, 5+, 6+ AT 4.66 MIN

CHROMATOGRAM - 214 NM

Native 214 nm full-run detector readings



IDENTITY BY LC-MS

Triple quadrupole LC-MS, m/z 100-1400, +. Left: extracted ions; right: spectrum, 4.62-4.71 min





Compound	Ion	Expected m/z	Observed m/z	Mass from ion (Da)	Deviation	Apex (min)	Signal / noise	vs blank
● Retatrutide	4+ [M+4H]	1183.84	1183.80	4,731.2	-0.004%	4.66	127,807	3,729x
● Retatrutide	5+ [M+5H]	947.28	947.21	4,731.0	-0.008%	4.65	17,902	721x
● Retatrutide	6+ [M+6H]	789.57	789.59	4,731.5	+0.003%	4.66	133	6x

BASIS OF THE RESULTS	
Purity:	**214 nm area percent, blank-corrected; main peak 8.713 min; 1 peak counted above the 0.511% reporting limit; 1 injection(s)**
Amount:	**Quantified against a certified reference standard by external calibration.**
Identity:	**Conforms**
Identity (LC-MS):	**Co-eluting charge states, mass within 0.1%, none in the blank**

LC-MS identity: confirmed at the intact mass (Expected (M+4H)4+, (M+5H)5+, (M+6H)6+ m/z peaks are observed together at 4.66 min and are absent from the blank; measured mass 4731.2 Da against 4731.3 Da expected (-0.004%)).

Results apply solely to the submitted sample as received; no conclusion is drawn on safety, efficacy, or regulatory status.
Verify this certificate: scan the QR code or visit testides.com/reports/DAYL-RETA-10-102626.